The going public of GPT Medical care closes for public registration today. The 525.14-crore IPO, which comes with a price band of 177-186, has actually subscribed 0.85 times. The marketplace great deal is 80 shares.
The issue consists of a fresh concern worth 40 crore and a sell (OFS) of as much as 2.608 crore shares (worth 485.14 crore) by capitalists offering investors.
As versus the offer of 1.97 crore shares (net-off support portion), the problem got bids for 1.68 crore shares.
BanyanTree, which holds 2.6 crore shares, or 32.64 per cent risk, in Kolkata-based GPT Medical care, is divesting its whole risk in the company through the IPO.
The offer is being made via guide Structure Process, in which at most 50 per cent of the deal will be readily available for allowance to Certified Institutional Purchasers, 15 per cent to non-institutional bidders and 35 percent to retail investors.
Retail financiers signed up for the IPO 1.25 times, while NIIs (high total assets people) bid for 0.79 times. QIBs’ part was subscribed 0.19 times.
As part of the IPO workout, GPT Health care raised 157.54 crore from anchor capitalists on Wednesday. The medical care significant that operates and takes care of mid-sized multispecialty medical facilities under the ILS Hospitals brand has set aside about 84.70 lakh shares at 186 a share to international and domestic Institutions.
Amongst the support capitalists were Kotak Mutal Fund, Axis Mutual Fund, Bandhan Mutual Fund, Aditya Birla Life Insurance Policy, Societe Generale, Duro One Investments Limited, India Capital Development Fund, Copthall Mauritius, LC Pharos Multi-Strategy Fund, Subhkam Ventures and DE Shaw.
The business plans to utilise funds for repayment/prepayment, in full or in part, of all or a section of particular impressive borrowings from banks and banks and general business purposes.
GPT Healthcare provides a large range of clinical services in more than 35 specialities and extremely specialities, consisting of internal medication and diabetology, nephrology (including renal transplants), general and laparoscopic surgical procedure, obstetrics and gynaecology, crucial treatment, gastroenterology, orthopaedics and joint replacements, interventional cardiology, neurology, and neurosurgery, paediatrics, and neonatology.
JM Financial Ltd is the single book-running lead manager to the Issue and Link Intime India Private Limited is the registrar of the offer. The equity shares are suggested to be listed on the BSE and NSE.